Find in Library

Background Gastric cancer has a low overall survival rate worldwide, and surgery remains the only intent to cure option at the early stages of the disease. HER-2 positive cancers may have a survival advantage. We present a patient with stage IV gastric cancer HER-2 positive responsive to Herceptin, free of detectable disease two years after surgery. Patient Presentation Seventy years old Caucasian male complained of left-sided chest pain. Upon evaluation, he was diagnosed with HER-2 positive adenocarcinoma of the stomach at the pylorus with two liver metastases. Near complete response was observed with Herceptin and cis-platinum based chemotherapy followed by 80% distal gastrectomy and liver resection with uneventful recovery. Two years follow up reported a patient living a normal life with undetectable disease. Conclusion Multimodality targeted therapy may accomplish twenty-four months cure of advanced malignant gastric disease.